Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al; Nykode’s $45M place­ment; Ideaya’s post-ES­MO of­fer­ing

Plus, news from Skye Bio­science, Me­di­ar Ther­a­peu­tics and Servi­er.

A first look at Ex­ci­sion’s HIV gene edit­ing clin­i­cal tri­al: The com­pa­ny said Wednes­day that three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER